![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Phase 1a Study of the Safety, Tolerability and Pharmacokinetics of ABI-H2158, a Novel Second-Generation HBV Core Inhibitor, In Healthy Volunteers
|
|
|
Reported by Jules Levin
EASL 2019 April 10-14 Vienna
E.J. Gane,1C. Schwabe,1M. Evanchik,2E. Ruby,2R. Colonno,2K. Alves,2S. Liaw,2and U. Lopatin2
1Clinical Trial Unit, Auckland Clinical Studies, Auckland, New Zealand; 2Assembly Biosciences, Inc., San Francisco, California, USA
Download the PDF here
![0429191](../images/042919/042919-9/0429191.gif)
![0429192](../images/042919/042919-9/0429192.gif)
![0429193](../images/042919/042919-9/0429193.gif)
![0429194](../images/042919/042919-9/0429194.gif)
![0429195](../images/042919/042919-9/0429195.gif)
![0429196](../images/042919/042919-9/0429196.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|